All News

In a rush for a quick update on selected trial results in #lupus presented at #EULAR2022? Please find my article https://t.co/0XTkPRr6kQ @RheumNow

SLE trials update: some good and bad news | RheumNow

#POS0716 #EULAR2022 Systematic review and meta-analysis of 7 studies (i.e. only 1 x proof of concept RCT) showed high SRI-4 response rate (82%) in #lupus patients treated on IL2. Injection reaction (33%) and Fever (24%). Promising and definitive RCT is needed @RheumNow https://t.co/BBcgt11yNT

#POS0713 #EULAR2022 Exploratory analyses from Phase 2 RCT showed numerically more patients treated with BIIB059, a BDCA2 inhibitor achieved a clear (CLASI of 0-1) and almost clear cutaneous #lupus (CLASI 0-3). Looking forward to Phase 3 results in the next few years @RheumNow https://t.co/dDbwYCx7zT

Watch: EULAR 2022 - Day 1 Faculty Recap Pane Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more. https://t.co/OBLt7dOMa3 https://t.co/lHmEOIFIGa

https://bit.ly/3GF2mOG

#POS0709 #EULAR2022 Pooled analyses of TULIP-1 & -2 RCTs showed sustained & #lupus patients spent longer time in BICLA response vs Placebo up to 52 Wks. BILAG response was sustained in MSK, skin and constitutional domains. Be interesting to see longer follow-up data @RheumNow https://t.co/kNk7WFloLf

B-cell depletion w/ RTX ttmt is FcγR dependant & affected by FcγRs variants 🧬 FCGR3A-158V: *encodes the allotype ⬆️ affinity for IgG1 *is associated w/ clinical and biological responses in RA and SLE. A new way to stratify pts for anti-CD20 therapy? @Yuz6Yusof #EULAR2022 OP0190 https://t.co/GPiaQXaF71

“I would not use rituximab unless I have to; use it in vasculitis/SLE nephritis, but for RA, you have other options.” – Prof. I McGinnes #EULAR2022 @rheumnow

#SLE Pts vaccinated against #COVID don’t have an ⬆️risk of flare and it works and all pts should be vaccinated: K Hyrich @eular_org #EULAR2022 @RheumNow session: Types if vaccine and how they work. https://t.co/Dkl8mTQpkj

#EULAR2022 Prof Pascual gave a great talks on use of transcriptomic analysis in stratifying #lupus & disease understanding. Tour de force from blood IFN signature use to Plasmablast (correlate with activity inc. in African) and Neutrophil/myeloid signatures (nephritis) @RheumNow https://t.co/tiX55ARDvC

Prof T Dorner summarizes what's new in #SLE #EULAR2022 @rheumnow https://t.co/YT0Ocw7I41

Interestingly, anti-IFN Ab can be present in #SLE pts and impact the IFN signature. There is a bimodal type I IFN signature in #SLE. IFN and Blys signatures overlap (?distinct populations/interactions between the two?) - Prof T Dorner #EULAR2022 @rheumnow https://t.co/phLXv2KVxR

#OP0142 #EULAR2022 Morand compared LLDAS in Early (<1yr) and Established #lupus. Although Early were younger & had higher disease activity, time-to-LLDAS was shorter. LLDAS was protective of flare in both. Should target for LLDAS early in diagnosis to improve outcomes @RheumNow https://t.co/7i9c69YkR3

In people without SLE who have severe COVID19 infection, autoAb against IFN-1 assc w/increased mortality Prof T Dorner #EULAR2022 @rheumnow https://t.co/nt2gACUtkL

New #SLE drug to pay attention to! iberdomide target Ikaros and Aiolos, reduce B cell, reduce autoAb and reduce IFN sig while enhancing regulatory T cells- Prof T Dorner #EULAR2022 @rheumnow https://t.co/q39pxK3gFJ

#ClinicalPearl #SLE Rx tomorrow? Combine #Ritux+#Belimumab variable response, CART Rx for severe refractory #lupus, antiCD38i, drugs i. RCTs=hope for pts. #EULAR2022 T Dorner @RheumNow @eular_org https://t.co/2BReU5bhG0

No need to switch TNFi during pregnancy. Study compared high placental vs. low placental transfer TNFi- no sig difference for SIE in childhood. Dr. L Flatman comparing different TNFi in pregnancy: 26,000 offsprings #EULAR2022 @rheumnow OP0130 https://t.co/IF5hepQoHc

#SLE hospitalized pts had worse outcomes than matched controls ? Due to interfonopathy and poor handling of viral infections - worse if #Rituximab or #MMF T Dormer BUT vaccination works if enough B cells responding to #Covid vaccine #EULAR2022 #Lupus scientific session @RheumNow https://t.co/MBb3Dvxmqp

Million $$$ questions presented to Prof T Dorner: anifrolumab vs. belimumab for #SLE? He prefers belimumab d/t more data on multiple organ manifestations ^ it might be protective in pts w/ COVID19 infection. If skin dz is predominant, then anifrolumab #EULAR2022 @rheumnow

#Belimumab safety in pregnancy EudraVigilance database retrospect study 47 preg: BEL stopped 1st trimester (group A) vs. cont'd (group B) - no diff in fetal death - more preterm birth/low birth weight, congenital malform'n in group A (not stat sig) #EULAR2022 @rheumnow POS0705 https://t.co/sLQ3MHNcWa

#COVIDvaccine is effective in active and inactive #SLE disease. Noted reduced response for MMF, MTX, GC>10 mg/day. Threshold of B cells is 9+ cell/uL to have a vaccine response. Prof T Dorner #EULAR2022 @rheumnow https://t.co/qyNUZxMccD

Topics

All News

Do you get our email newsletter?